Antibody–drug conjugates (ADCs) continue to redefine targeted therapy by combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Central to the therapeutic performance of ADCs is the antibody–target interaction, whose binding kinetics determine the strength and duration of target engagement. As the ADC landscape broadens across both targets and payloads, these kinetics can serve as a key factor in candidate optimization and differentiation.

Surface plasmon resonance (SPR) is a powerful, label-free technique for studying molecular interactions in real time. In our ResidenceTimer™ platform, this technique is applied to diverse binding systems, including small molecule–protein, protein–protein and multi-component interactions. In a new case study published on our website, we demonstrate how different SPR approaches can be applied to determine and compare binding kinetics across ADCs and antibodies, using TROP2-targeted agents as an illustrative example.

Our support of your ADC discovery and development programs also goes beyond our ResidenceTimer™ platform. With our Oncolines panel of 102 cancer cell lines we can broadly profile ADCs and identify drug response biomarkers. Moreover, our collection of cancer cell lines can be used for cell surface receptor quantification to select relevant models, measurement of ADC internalization and evaluation of synergistic effects within dual/multi-payload ADCs or between ADCs and other agents. As part of the O.N.E Symeres integrated platform, we additionally offer synthesis of linker–payload combinations, drug-to-antibody ratio (DAR) analysis and ADC stability testing.

Interested in more information about our services? Contact us via services@oncolines.com.